153 related articles for article (PubMed ID: 11042579)
1. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
Smith MR; Kaufman D; Oh W; Guerin K; Seiden M; Makatsoris T; Manola J; Kantoff PW
Cancer; 2000 Oct; 89(8):1824-8. PubMed ID: 11042579
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P
Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
Carles J; Domenech M; Gelabert-Mas A; Nogue M; Tabernero JM; Arcusa A; Guasch I; Miguel A; Ballesteros JJ; Fabregat X
Acta Oncol; 1998; 37(2):187-91. PubMed ID: 9636014
[TBL] [Abstract][Full Text] [Related]
7. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.
Vaishampayan U; Fontana J; Du W; Hussain M
Urology; 2002 Dec; 60(6):1050-4. PubMed ID: 12475668
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer.
Attivissimo LA; Fetten JV; Kreis W
Am J Clin Oncol; 1996 Dec; 19(6):581-3. PubMed ID: 8931676
[TBL] [Abstract][Full Text] [Related]
9. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.
Sweeney CJ; Monaco FJ; Jung SH; Wasielewski MJ; Picus J; Ansari RH; Dugan WM; Einhorn LH
Ann Oncol; 2002 Mar; 13(3):435-40. PubMed ID: 11996476
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.
Carles J; Nogue M; Sole JM; Foro P; Domenech M; Suarez M; Gallardo E; García D; Ferrer F; Gelabert-Mas A; Gayo J; Fabregat X
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1085-91. PubMed ID: 19577864
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer.
Carles Galcerán J; Bastus Piulats R; Martín-Broto J; Maroto Rey P; Nogué Aligué M; Domenech Santasusana M; Arcusa Lanza A; Bellmunt Molins J; Colin C; Girard A
Clin Transl Oncol; 2005 Mar; 7(2):66-73. PubMed ID: 15899211
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Oudard S; Caty A; Humblet Y; Beauduin M; Suc E; Piccart M; Rolland F; Fumoleau P; Bugat R; Houyau P; Monnier A; Sun X; Montcuquet P; Breza J; Novak J; Gil T; Chopin D
Ann Oncol; 2001 Jun; 12(6):847-52. PubMed ID: 11484963
[TBL] [Abstract][Full Text] [Related]
13. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
Hudes G; Einhorn L; Ross E; Balsham A; Loehrer P; Ramsey H; Sprandio J; Entmacher M; Dugan W; Ansari R; Monaco F; Hanna M; Roth B
J Clin Oncol; 1999 Oct; 17(10):3160-6. PubMed ID: 10506613
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer.
Koletsky AJ; Guerra ML; Kronish L
Cancer J; 2003; 9(4):286-92. PubMed ID: 12967139
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.
Sewak S; Chachoua A; Hamilton A; Taneja S; Lee J; Utate M; Sorich J; Muggia FM
Anticancer Drugs; 2003 Jan; 14(1):67-72. PubMed ID: 12544260
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study.
Morant R; Hsu Schmitz SF; Bernhard J; Thürlimann B; Borner M; Wernli M; Egli F; Forrer P; Streit A; Jacky E; Hanselmann S; Bauer J; Hering F; Schmid HP
Eur J Cancer; 2002 Aug; 38(12):1626-32. PubMed ID: 12142053
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
18. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
Tester W; Ackler J; Tijani L; Leighton J
Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
